August 2, 2021


Camber's Vertical Integration and Expansion Is Key to Strong Supply Chain

Camber's Vertical Integration and Expansion Is Key to Strong Supply Chain
The parent company of Camber Pharmaceuticals, Hetero Drugs of Hyderabad, India, is investing heavily in research and development (R&D) and infrastructure to keep pace with the expanding generics marketplace. Their research and development efforts are focused on more complex molecules, including oncology, antivirals, hepatitis C, and biosimilars.

With more than 25 manufacturing facilities across the globe, including 5 plants in special economic zones, Hetero can produce more than 50 billion oral doses annually. Hetero offers the largest campus of application program interface reactor capacities in the world, allowing Camber to be vertically integrated on more than 90% of its product line. Hetero employs approximately 15,000 associates in more than 120 countries worldwide.
New Facilities in the United States and India Increase Capacities
At 3 different plants in India, Hetero has more than doubled its capacities by adding over 1 million square feet to its total manufacturing and warehouse space, which now exceeds 2.5 million square feet dedicated solely to the US marketplace. In the United States, Hetero is building a new 310,000-square-foot state-of-the-art manufacturing facility in Central Islip, New York, for Camber’s sister company, Ascent Pharmaceuticals, which will open in early 2018. In addition, Hetero recently purchased an existing 110,000-square-foot facility nearby in Long Island. These timely investments in R&D and infrastructure will ensure that Camber maintains a robust pipeline and reliable supply of products that meet the needs of customers and patients alike for years to come.

Camber’s Pipeline Features Products From New US Facility
In addition to Camber’s recent launch of 15-mg and 30-mg Oxycodone HCl Tablets (Roxicodone) 100 and 500 count, and 240-mL bottles of Abacavir Oral Solution (Ziagen) 20 mg/mL, the new pipeline includes several controlled substances and future products from the new Ascent Pharmaceuticals facility. Products scheduled to launch in the last quarter of 2017 include:
  • Tolterodine Tartrate ER Capsules (Detrol LA) 2 mg and 4 mg
  • Hydromorphone Oral Solution (Dilaudid) 5mg/5mL
Camber’s current portfolio includes 48 products (164 stock-keeping unit), 43 of which are manufactured by Hetero Drugs and 5 manufactured by Ascent Pharmaceuticals. Camber’s future pipeline includes 55 abbreviated new drug applications (ANDAs) filed or under review and more than 15 ANDAs projected for release in 2017. 

In addition to a highly competitive portfolio, Camber is notable for a strong supply chain, exceptional customer service, and a dedicated team of seasoned sales professionals with deep experience in the generics industry. Camber’s goal is to provide a sustainable, long-term competitive advantage to every customer.

Camber’s commitment to the patient is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us   Privacy